Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 20/20 | 0.52 |
| ▸ | ITGAV | P06756 | 20/20 | 0.52 |
| ▸ | ITGB5 | P18084 | 6/20 | 0.52 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.52 |
| ▸ | ITGB6 | P18564 | 2/20 | 0.52 |
| ▸ | ITGA5 | P08648 | 11/20 | 0.44 |
| ▸ | ITGB1 | P05556 | 9/20 | 0.44 |
| ▸ | ITGB8 | P26012 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12877993 | 0.87 | ITGB3 (0.55) | ITGB3ITGAVITGB5ITGA2BITGB6 | |
| Cilengitide SCHEMBL16920496 | 0.84 | ITGB3 (0.59) | ITGB3ITGAVITGB5ITGA2BITGB6 | |
| Cilengitide SCHEMBL451423 | 0.84 | ITGB3 (0.59) | ITGB3ITGAVITGB5ITGA2BITGB6 | |
| Cilengitide SCHEMBL22594705 | 0.84 | ITGB3 (0.59) | ITGB3ITGAVITGB5ITGA2BITGB6 | |
| SCHEMBL19581485 | 0.83 | ITGB3 (0.51) | ITGB3ITGAVITGB5ITGA2BITGB6 | |
| SCHEMBL12016720 | 0.81 | ITGB3 (0.46) | ITGB3ITGAVITGB5ITGA2BITGB6 | |
| Cilengitide SCHEMBL19534260 | 0.79 | ITGB3 (0.78) | ITGB3ITGAVITGB5ITGA2BITGB6 | |
| Cilengitide SCHEMBL26970603 | 0.79 | ITGB3 (0.78) | ITGB3ITGAVITGB5ITGA2BITGB6 | |
| Cilengitide SCHEMBL34082 | 0.79 | ITGB3 (0.78) | ITGB3ITGAVITGB5ITGA2BITGB6 | |
| Cilengitide SCHEMBL29403053 | 0.79 | ITGB3 (0.77) | ITGB3ITGAVITGB5ITGA2BITGB6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2509583-B1 | PHARMACEUTICAL COMPOSITION COMPRISING OLIGOPEPTIDES, PREFERABLY CILENGITIDE | MERCK PATENT GMBH (DE) | 2019-05-15 | — | — | EP | disclosed |
| EP-2717854-B1 | TREATMENT OF CANCERS AND METASTASES WITH SUSPENSIONS OF CILENGITIDE IN CARRIER | MERCK PATENT GMBH (DE) | 2019-01-16 | — | — | EP | disclosed |
| EP-3085704-A1 | NOVEL SOLID MATERIALS OF {[(2S, 5R, 8S, 11S)-5-BENZYL-11-(3-GUANIDINO-PROPYL)-8-ISOPROPYL-7-METHYL-3,6,9,12,15-PENTAOXO-1,4,7,10,13-PENTAAZA-CYCLOPENTADEC-2-YL]-ACETIC ACID} AND METHODS FOR OBTAINING THEM | Merck Patent GmbH (DE) | 2016-10-26 | — | — | EP | disclosed |
| EP-3085704-A1 | NOVEL SOLID MATERIALS OF {[(2S, 5R, 8S, 11S)-5-BENZYL-11-(3-GUANIDINO-PROPYL)-8-ISOPROPYL-7-METHYL-3,6,9,12,15-PENTAOXO-1,4,7,10,13-PENTAAZA-CYCLOPENTADEC-2-YL]-ACETIC ACID} AND METHODS FOR OBTAINING THEM | Merck Patent GmbH (DE) | 2016-10-26 | — | — | EP | disclosed |
| EP-3085704-A1 | NOVEL SOLID MATERIALS OF {[(2S, 5R, 8S, 11S)-5-BENZYL-11-(3-GUANIDINO-PROPYL)-8-ISOPROPYL-7-METHYL-3,6,9,12,15-PENTAOXO-1,4,7,10,13-PENTAAZA-CYCLOPENTADEC-2-YL]-ACETIC ACID} AND METHODS FOR OBTAINING THEM | Merck Patent GmbH (DE) | 2016-10-26 | — | — | EP | disclosed |
| US-9433577-B2 | Pharmaceutical composition comprising oligopeptides | MERCK PATENT GMBH (DE) | 2016-09-06 | — | — | US | disclosed |
| EP-2432801-B1 | NOVEL SOLID MATERIALS OF {[2S, 5R,8S,11S)-5-BENZYL-11-(3-GUANIDINO-PROPYL)-8-ISOPROPYL-7-METHYL-3,6,9,12,15-PENTAOXO-1,4,7,10,13-PENTAAZA-CYCLOPENTADEC-2-YL]-ACETIC ACID} AND METHODS FOR OBTAINING THEM | MERCK PATENT GMBH (DE) | 2016-03-23 | — | — | EP | disclosed |
| US-8765684-B2 | Solid materials of {[(2S,5R,8S,11S)-5-benzyl-11-(3-guanidino-propyl)-8-isopropyl-7-methyl-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid} and methods for obtaining them | MERCK PATENT GMBH (DE) | 2014-07-01 | — | — | US | disclosed |
| US-8765684-B2 | Solid materials of {[(2S,5R,8S,11S)-5-benzyl-11-(3-guanidino-propyl)-8-isopropyl-7-methyl-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid} and methods for obtaining them | MERCK PATENT GMBH (DE) | 2014-07-01 | — | — | US | disclosed |
| US-8765684-B2 | Solid materials of {[(2S,5R,8S,11S)-5-benzyl-11-(3-guanidino-propyl)-8-isopropyl-7-methyl-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid} and methods for obtaining them | MERCK PATENT GMBH (DE) | 2014-07-01 | — | — | US | disclosed |
| US-20120288539-A1 | PHARMACEUTICAL COMPOSITION COMPRISING OLIGOPEPTIDES | MERCK PATENT GMBH (DE) | 2012-11-15 | — | — | US | disclosed |
| EP-2509583-A2 | PHARMACEUTICAL COMPOSITION COMPRISING OLIGOPEPTIDES, PREFERABLY CILENGITIDE | Merck Patent GmbH (DE) | 2012-10-17 | — | — | EP | disclosed |
| EP-2432801-A2 | NOVEL SOLID MATERIALS OF {[2S, 5R,8S,11S)-5-BENZYL-11-(3-GUANIDINO-PROPYL)-8-ISOPROPYL-7-METHYL-3,6,9,12,15-PENTAOXO-1,4,7,10,13-PENTAAZA-CYCLOPENTADEC-2-YL]-ACETIC ACID} AND METHODS FOR OBTAINING THEM | Merck Patent GmbH (DE) | 2012-03-28 | — | — | EP | disclosed |
| EP-2432801-A2 | NOVEL SOLID MATERIALS OF {[2S, 5R,8S,11S)-5-BENZYL-11-(3-GUANIDINO-PROPYL)-8-ISOPROPYL-7-METHYL-3,6,9,12,15-PENTAOXO-1,4,7,10,13-PENTAAZA-CYCLOPENTADEC-2-YL]-ACETIC ACID} AND METHODS FOR OBTAINING THEM | Merck Patent GmbH (DE) | 2012-03-28 | — | — | EP | disclosed |
| US-20120065142-A1 | NOVEL SOLID MATERIALS OF AND METHODS FOR OBTAINING THEM | MERCK PATENT GMBH (DE) | 2012-03-15 | — | — | US | disclosed |
| US-20120065142-A1 | NOVEL SOLID MATERIALS OF AND METHODS FOR OBTAINING THEM | MERCK PATENT GMBH (DE) | 2012-03-15 | — | — | US | disclosed |
| WO-2010133367-A3 | NOVEL SOLID MATERIALS OF {[2S, 5R,8S,11S)-5-BENZYL-11-(3-GUANIDINO-PROPYL)-8-ISOPROPYL-7-METHYL-3,6,9,12,15-PENTAOXO-1,4,7,10,13-PENTAAZA-CYCLOPENTADEC-2-YL]-ACETIC ACID} AND METHODS FOR OBTAINING THEM | MERCK PATENT GMBH (DE) | 2011-10-27 | — | — | WO | disclosed |
| WO-2011069629-A2 | PHARMACEUTICAL COMPOSITION COMPRISING OLIGOPEPTIDES | MERCK PATENT GMBH (DE) | 2011-06-16 | — | — | WO | disclosed |
| WO-2010133367-A2 | NOVEL SOLID MATERIALS OF {[2S, 5R,8S,11S)-5-BENZYL-11-(3-GUANIDINO-PROPYL)-8-ISOPROPYL-7-METHYL-3,6,9,12,15-PENTAOXO-1,4,7,10,13-PENTAAZA-CYCLOPENTADEC-2-YL]-ACETIC ACID} AND METHODS FOR OBTAINING THEM | MERCK PATENT GMBH (DE) | 2010-11-25 | — | — | WO | disclosed |
| WO-2010133367-A2 | NOVEL SOLID MATERIALS OF {[2S, 5R,8S,11S)-5-BENZYL-11-(3-GUANIDINO-PROPYL)-8-ISOPROPYL-7-METHYL-3,6,9,12,15-PENTAOXO-1,4,7,10,13-PENTAAZA-CYCLOPENTADEC-2-YL]-ACETIC ACID} AND METHODS FOR OBTAINING THEM | MERCK PATENT GMBH (DE) | 2010-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120288539-A1 | PHARMACEUTICAL COMPOSITION COMPRISING OLIGOPEPTIDES | VIP, LNPEP, IAPP | ITGB3 2678/4885ITGAV 2500/4885ITGB5 2842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.